ARTSaVIT is an Israeli cancer apoptosis company housed in the Merck Ventures Israel BioIncubator. The insights gathered by Prof. Larisch and the unique function of ARTS led to the establishment of the company, which is developing small molecule ARTS mimetics designed to selectively induce apoptosis in cancer cells.

Team Members
more about
Jasper Bos
more about
Jeroen Bakker
more about
Anna Chase
Latest News Entry
ARTSaVIT Ltd. Completes $6.3 Million Series A Financing

YAVNE, Israel, January 5, 2016 - Israeli cancer apoptosis company ARTSaVIT LTD announced today that it has completed a $6.3 million Series A round of financing led by Arkin Bio Ventures and Pontifax, with participation of Merck Ventures, Carmel Innovation and Carmel - Haifa University Economic Corporation Ltd.

all portfolio news